Puma Biotechnology (PBYI) Share-based Compensation (2012 - 2026)
Puma Biotechnology's (PBYI) quarterly Share-based Compensation came in at $1.7 million in Q1 2026, down 16.09% YoY from $2.0 million in Q1 2025, and up 5.13% on a QoQ basis from $1.6 million in Q4 2025.
Puma Biotechnology (PBYI) Share-based Compensation (2012 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 15 years of Share-based Compensation data on file, last reported at $1.7 million in Q1 2026.
- Quarterly Share-based Compensation fell 16.09% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (down 78.46% YoY) and the FY2025 annual result came in at $6.9 million, down 15.78% from the prior year.
- Share-based Compensation grew to $1.7 million in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $3.2 million in Q2 2022 to a low of $700000.0 in Q3 2025.
- A 5-year average of $2.2 million and a median of $2.4 million in 2024 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 117.78% in 2022, down 82.35% in 2022.
- Tracing PBYI's Share-based Compensation over 5 years: stood at $2.6 million in 2022, then slipped by 7.46% to $2.4 million in 2023, then fell by 27.96% to $1.8 million in 2024, then decreased by 7.71% to $1.6 million in 2025, then increased by 5.13% to $1.7 million in 2026.
- The last three Share-based Compensation figures came in at $1.7 million (Q1 2026), $1.6 million (Q4 2025), and $700000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 1.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.95 Mn |
| Jun 30, 2026 | 1.95 Mn |
| Mar 31, 2026 | 1.70 Mn |
| Mar 31, 2026 | 1.70 Mn |
| Dec 31, 2025 | 1.62 Mn |
| Dec 31, 2025 | 1.62 Mn |
| Sep 30, 2025 | 700,000.00 |
| Sep 30, 2025 | 700,000.00 |
| Jun 30, 2025 | 1.63 Mn |
| Jun 30, 2025 | 1.63 Mn |
| Mar 31, 2025 | 2.03 Mn |
| Mar 31, 2025 | 2.03 Mn |
| Dec 31, 2024 | 1.75 Mn |
| Dec 31, 2024 | 1.75 Mn |
| Sep 30, 2024 | 2.05 Mn |
| Sep 30, 2024 | 2.05 Mn |
| Jun 30, 2024 | 2.06 Mn |
| Jun 30, 2024 | 2.06 Mn |
| Mar 31, 2024 | 2.38 Mn |
| Mar 31, 2024 | 2.38 Mn |